PL366855A1 - Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof - Google Patents

Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof

Info

Publication number
PL366855A1
PL366855A1 PL02366855A PL36685502A PL366855A1 PL 366855 A1 PL366855 A1 PL 366855A1 PL 02366855 A PL02366855 A PL 02366855A PL 36685502 A PL36685502 A PL 36685502A PL 366855 A1 PL366855 A1 PL 366855A1
Authority
PL
Poland
Prior art keywords
active ingredients
aryl substituted
combination preparations
propanolamine derivatives
substituted propanolamine
Prior art date
Application number
PL02366855A
Other languages
English (en)
Polish (pl)
Inventor
Heiner Glombik
Wendelin Frick
Hans-Ludwig Schaefer
Werner Kramer
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10140170A external-priority patent/DE10140170A1/de
Priority claimed from DE2001142455 external-priority patent/DE10142455A1/de
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of PL366855A1 publication Critical patent/PL366855A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
PL02366855A 2001-08-22 2002-08-09 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof PL366855A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10140170A DE10140170A1 (de) 2001-08-22 2001-08-22 Kombinationspräparate von arylsubstituierten Propanolaminderivaten mit weiteren Wirkstoffen und deren Verwendung
DE2001142455 DE10142455A1 (de) 2001-08-31 2001-08-31 Kombinationspräparate von arylsubstituierten Propanolderivaten mit weiteren Wirkstoffen und deren Verwendung

Publications (1)

Publication Number Publication Date
PL366855A1 true PL366855A1 (en) 2005-02-07

Family

ID=26009945

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366855A PL366855A1 (en) 2001-08-22 2002-08-09 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof

Country Status (21)

Country Link
US (1) US20030158094A1 (https=)
EP (1) EP1420826A2 (https=)
JP (1) JP2005505538A (https=)
KR (1) KR20040027963A (https=)
CN (1) CN1638801A (https=)
AR (1) AR035284A1 (https=)
BR (1) BR0211995A (https=)
CA (1) CA2457974A1 (https=)
CO (1) CO5560569A2 (https=)
HR (1) HRP20040172A2 (https=)
HU (1) HUP0401908A2 (https=)
IL (1) IL160475A0 (https=)
MX (1) MXPA04001256A (https=)
NO (1) NO20040726L (https=)
NZ (1) NZ531292A (https=)
PA (1) PA8553101A1 (https=)
PE (1) PE20030358A1 (https=)
PL (1) PL366855A1 (https=)
RU (1) RU2004108120A (https=)
UY (1) UY27418A1 (https=)
WO (1) WO2003018059A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023245A (en) * 1987-11-10 1991-06-11 Hauser-Kuhrts, Inc. Improved niacin formulation
DK0869121T3 (da) * 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater
DE19845402B4 (de) * 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845405C2 (de) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE69911058T2 (de) * 1998-12-23 2004-06-03 G.D. Searle Llc, Chicago Kombinationen einem ibat inhibitor und einem mtp inhibitor für kardiovaskuläre indikationen

Also Published As

Publication number Publication date
JP2005505538A (ja) 2005-02-24
WO2003018059A3 (de) 2003-11-13
PA8553101A1 (es) 2003-06-30
BR0211995A (pt) 2004-09-28
AR035284A1 (es) 2004-05-05
CA2457974A1 (en) 2003-03-06
RU2004108120A (ru) 2005-04-10
MXPA04001256A (es) 2004-05-27
US20030158094A1 (en) 2003-08-21
CN1638801A (zh) 2005-07-13
KR20040027963A (ko) 2004-04-01
CO5560569A2 (es) 2005-09-30
HUP0401908A2 (hu) 2005-01-28
NO20040726L (no) 2004-02-19
IL160475A0 (en) 2004-07-25
EP1420826A2 (de) 2004-05-26
WO2003018059A2 (de) 2003-03-06
PE20030358A1 (es) 2003-04-23
NZ531292A (en) 2005-08-26
UY27418A1 (es) 2002-11-29
HRP20040172A2 (en) 2004-10-31

Similar Documents

Publication Publication Date Title
PL366855A1 (en) Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
IL158076A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
AU2002253619A1 (en) Heterocyclic compound and antitumor agent containing the same active ingredients
IL155071A0 (en) Glucopyranosyloxybenzylbenzene derivatives and medical compositions containing the same
ID22565A (id) Penggunaan nanodispersi dalam formulasi akhir obat
IL160474A0 (en) Combination products of 1,4-benzothiepine 1,1-dioxide derivatives with other active ingredients and the use thereof
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
IL193234A0 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
HUP0400723A3 (en) Isoxazoline derivatives and herbicide composition comprising the same as active ingredient
PT1757606E (pt) Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL158499A (en) Malononitrile compounds and their use in the manufacture of pesticide compositions
HUP0203563A3 (en) Fungicidal combinations of active substances and use thereof
HUP0401984A3 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions and combination with other active ingredients
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
AU2002333373A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
IL157908A0 (en) Phthalazinone derivatives and pharmaceutical compositions containing the same
IL157740A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
AU2003260241A1 (en) Buguzhi agent and composition and methods of preparing and administering the same
AU2001260418A1 (en) Use of ergothioneine and/or its derivatives as anti-pollution agent
HUP0203611A3 (en) 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
IL159085A0 (en) Heterocyclic derivatives and pharmaceutical compositions containing the same
NO20014692L (no) 3-amidinobenzensulfonamidderivater, medisinske sammensetninger inneholdende slike samt intermediater vedfremstillingen derav

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)